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During the past decade, the incidence and severity of Clostridium difficile infection (CDI) have signifi-
cantly increased, leading to a rise in CDI-associated hospitalizations, health care costs, and mortality.
Although treatment options exist for CDI, recurrence is frequent following treatment. Furthermore,
patients with at least one CDI recurrence are at an increased risk of developing additional recurrences.
A novel approach to the prevention of recurrent CDI is the use of monoclonal antibodies directed
against the toxins responsible for CDI as an adjunct to antibiotic treatment. Bezlotoxumab, a human
monoclonal antibody that binds and neutralizes C. difficile toxin B, is the first therapeutic agent to
receive United States Food and Drug Administration approval for the prevention of CDI recurrence.
Clinical studies have demonstrated superior efficacy of bezlotoxumab in adults receiving antibiotic
therapy for CDI compared with antibiotic therapy alone for the prevention of CDI recurrence. Bezlo-
toxumab was well tolerated in clinical trials, with the most common adverse effects being nausea, vom-
iting, fatigue, pyrexia, headache, and diarrhea. The demonstrated efficacy, safety, and characteristics of
bezlotoxumab present an advance in prevention of CDI recurrence.
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Clostridium difficile infection (CDI) is a sub-
stantial burden to patients and families and is
associated with considerable morbidity and mor-
tality.1–3 In the United States in 2011, C. difficile
was responsible for nearly 500,000 infections
and approximately 29,000 deaths.4 Furthermore,
the direct costs of CDI in acute care settings in
the United States were estimated to be $4.8 bil-
lion in 2008.5 However, the actual costs are
likely higher when indirect costs of CDI man-
agement are considered.
Currently available treatment options for ini-
tial CDI include metronidazole, oral van-
comycin, and fidaxomicin. Although treatment
for primary CDI is successful in many cases,
CDI recurrence is common. There is at least one
recurrence within the first 2 months of initial
treatment with metronidazole or vancomycin in
13–47% of patients.6–8 After the first occurrence,
patients have a 38–45% chance of a second CDI
recurrence, and this risk increases with each
subsequent CDI recurrence.6–8 It has been esti-
mated that there were between 77,299 and
231,898 episodes of recurrent CDI, for approxi-
mately 560,419 to 715,018 total cases of CDI in
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the United States in 2011.9 Compared to pri-
mary CDI, recurrent CDI is associated with a
2.5-fold higher hospital readmission rate and a
33% higher mortality rate at 180 days, highlight-
ing the critical need for multifaceted successful
interventions.10, 11
The association between a healthy gut micro-
biota and protection against CDI has been well
established in both animal and human mod-
els.12–14 Several factors play a role in the dysbio-
sis of the host gut microbiota, weakening the
host’s natural defense system against CDI.
Antibiotic use is the most important risk fac-
tor for CDI and CDI recurrence.15, 16 Although
certain antibiotics such as fluoroquinolones,
clindamycin, and cephalosporins are associated
with a high risk for CDI, any antibiotic that
alters the normal gut microbiota can lead to CDI
recurrence, including antibiotics used for CDI
treatment.17 Following a CDI treatment course,
gut dysbiosis persists for a period of time until
the gut microbiota reestablishes itself. C. difficile
spores are able to germinate and reinfect the gut
during this period of susceptibility after antibiotic
discontinuation.3, 18 Advanced age (> 65 yrs),
prior episodes of CDI, immunosuppressing dis-
ease states, and acid-suppressing drugs (proton
pump inhibitors) are also important risk factors
for CDI recurrence.19–21 Although some studies
suggest no association, other studies have identi-
fied an association between the acquisition of
the hypervirulent BI/NAP1/027 strain and higher
rates of CDI recurrence.22, 23
Several nonpharmacologic interventions may
reduce the incidence of health care–associated
CDI with varying degrees of success. These
include use of contact isolation precautions for
patients with CDI, enhanced environmental dis-
infection, handwashing with soap and water,
clinician education on appropriate C. difficile
testing, and the implementation of antimicrobial
stewardship programs to decrease the inappro-
priate use of antibiotic therapy.24–29 However,
these interventions have not led to a consistent
or widespread decline in CDI rates.30 Fidax-
omicin is an effective treatment option for first
or second CDI episodes and has been associ-
ated with a reduced rate of relapse compared
to oral vancomycin, but it does not appear to
be any more effective for patients with recur-
rent CDI.7, 31 The use of probiotics has been
controversial, where some controlled trials
show benefit and others do not.32, 33 Probiotics
lack U.S. Food and Drug Administration
(FDA)-approved indications for CDI, and the
term “probiotics” encompasses several different
available products with varying degrees of effi-
cacy.33 There has also been inconsistent evi-
dence with different adjuvant therapies such as
ion-exchange resins, whole bowel irrigation,
rifaximin, and nitazoxanide.34 High cure rates
for recurrent CDI have been demonstrated with
fecal microbiota transplantation (FMT), but
multiple factors and practical considerations
may pose potential barriers to successful FMT
administration.35–37 Lack of standardized fecal
delivery techniques and sources, lack of con-
sensus on when and in what setting FMT
should be pursued, third-party reimbursement
considerations, and unknown utility of FMT
during continued antibiotic therapy limit adop-
tion of this modality.37, 38 Thus, there is an
urgent need for additional strategies to reduce
the incidence of CDI recurrence.38 Monoclonal
antibodies actotoxumab, directed against C. dif-
ficile toxins A (TcdA), and bezlotoxumab,
directed against toxin B (TcdB) have been pur-
sued as therapeutic agents to prevent CDI
recurrence.
Bezlotoxumab (Zinplava [formerly BLA
761046]; Merck & Co., Inc., Kenilworth, NJ), a
novel humanized monoclonal antibody targeted
against Clostridium difficile toxin B (TcdB), was
approved by the FDA on October 21, 2016.39–41
Bezlotoxumab is indicated to reduce recurrence
of CDI in patients aged 18 years or older who
are receiving antibacterial drug treatment for
CDI and are considered at high risk for
CDI recurrence.41 Bezlotoxumab is not an
antibiotic and should not be used for the treat-
ment of CDI. This review will highlight the
pharmacologic characteristics of bezlotoxumab
and clinical trials for its use to prevent recur-
rent CDI.
Pharmacology and Mechanism of Action
Two homologous exotoxins, TcdA and TcdB,
are predominantly responsible for the patho-
genic effects of CDI.42 These exotoxins lead to
an increase in gut wall permeability and an
acute proinflammatory response leading to diar-
rhea and potentially more severe symptoms of
CDI.43, 44 Targeting these toxins with serum
antitoxin antibodies affords the possibility of
passive immunity against recurrent CDI.45 Evi-
dence suggests that toxin inhibition is protec-
tive, as high titers of antitoxin antibodies
correlate with lower rates of primary and recur-
rent CDI in humans.46, 47 Antibody-bound toxin
is prevented from entering the gut endothelium
and causing cell damage.48, 49 Bezlotoxumab is an
immunoglobulin (Ig) of the IgG1 subclass, with
an approximate molecular weight of 148.2 kDa.41
Bezlotoxumab specifically binds to TcdB and neu-
tralizes the toxin-mediated effects associated with
CDI as depicted in Figure 1.
Pharmacodynamics
Bezlotoxumab binds with high affinity (Kd
19  5 pmol/L) to the N-terminal half of the
TcdB combined repetitive oligopeptide (CROP)
domain to partially block carbohydrate binding
pockets and to prevent toxin binding to host
colonocytes.50 In an in vitro study measuring
the neutralization potencies of bezlotoxumab
against TcdB from various C. difficile strains,
bezlotoxumab was shown to neutralize TcdB in
all strains tested.51 In this study, although bezlo-
toxumab showed lower neutralization potencies
for the hypervirulent strains BI/NAP1/027 and
BK/NAP7/078, neutralization of these toxins was
achieved at antibody concentrations below
plasma concentrations seen patients with CDI.
However, concentrations within the colon and
feces were not specifically assessed. In another
study, bezlotoxumab was shown to inhibit toxin
B–mediated tumor necrosis factor a and inter-
leukin-1b expression in human colon and
peripheral blood monocytes.52
Pharmacokinetics
According to a population pharmacokinetic
analysis, the geometric mean clearance of bezlo-
toxumab was 0.317 L/day with a mean volume
of distribution of 7.33 L and an elimination
half-life of 19 days.53 This long half-life allows
for administration of a single dose of bezlotox-
umab to achieve therapeutic serum concentra-
tions for an extended period of time to prevent
recurrent CDI episodes.53 When bezlotoxumab
was administered as a single intravenous dose of
10 mg/kg, the geometric mean area under the
curve from time zero extrapolated to infinity
was 53,000 lg hour/ml, and the maximum
serum concentration was 185 lg/ml. To our
knowledge, there are no data regarding distribu-
tion of bezlotoxumab or concentrations achieved
within the colonic lumen. Increased body weight
was associated with an increased clearance of
bezlotoxumab, and weight-based dosing
accounts for increased exposure differences.
Bezlotoxumab is completely eliminated by cata-
bolism and, therefore, has a low potential for
drug–drug interactions. Theoretically, no dis-
cernible drug–drug interactions are anticipated
when monoclonal antibodies are coadministered,
and the limited clinical observations support this
prediction.54 However, it is unknown if bezlo-
toxumab specifically interacts with other mono-
clonal antibodies. Of note, sex, race, ethnicity,
Figure 1. Bezlotoxumab binds and neutralizes Clostridium difficile toxin B (TcdB) to prevent TcdB from binding to the gut
endothelium.
and comorbid conditions had no appreciable
effect on exposure to bezlotoxumab.41
In patients with mild (estimated glomerular
filtration rate [eGFR] 60–89 ml/min), moderate
(eGFR 30–59 ml/min), or severe (eGFR 15–
29 ml/min) renal impairment or with end-stage
renal disease (eGFR < 15 ml/min), no clinically
meaningful differences in exposure were
found.41 Similarly, hepatic impairment (defined
as having at least two of the following: albumin
level ≤ 3.1 g/dl; alanine aminotransferase level
≥ 2 times the upper limit of normal; total biliru-
bin level ≥ 1.3 times the upper limit of normal;
or mild, moderate, or severe liver disease char-
acterized by Charlson Comorbidity Index) did
not yield clinically meaningful differences in
exposure.41
Dosage, Preparation, and Administration
The recommended dosage of bezlotoxumab is a
single 10-mg/kg dose administered as an intra-
venous infusion over 60 minutes.41 In phase 3
clinical trials, the median patient weight in the
bezlotoxumab group was 70.0 kg (range 29.8–
200 kg) and, therefore, the largest dose adminis-
tered was 2000 mg.41, 55 A numerically higher
number of serious adverse effects and deaths
occurred in patients who weighed ≤ 70 kg com-
pared to patients who weighed > 70 kg in all study
arms. According to product labeling, the dose
should be calculated based on actual body
weight.41 In clinical studies, bezlotoxumab was
administered at various time points during the
course of standard-of-care antibiotics for the treat-
ment of CDI.55 In the MODIFY I and MODIFY II
trials, bezlotoxumab infusion occurred at any time
point from the day prior to the initiation of antibi-
otic therapy to 14 days after the start of antibiotic
therapy.55 Bezlotoxumab was administered within
6 days after initiation of standard-of-care antibi-
otics in approximately 94% of patients, and the
median administration day was on day 3.55 Repeat
administrations of bezlotoxumab have not been
evaluated in clinical studies, and there is no clini-
cal experience with bezlotoxumab overdosing.41
Bezlotoxumab may be administered in the inpa-
tient or outpatient clinic setting. In phase 3 clinical
trials, 67.9% of participants received bezlotoxumab
as inpatients.55
Bezlotoxumab is commercially available as a
1000-mg/40-ml (25 mg/ml) solution in a single-
dose vial for intravenous use.41 The listed aver-
age wholesale price for a 1000-mg/40-ml vial is
$4560.56 The undiluted, single-dose vial should
be refrigerated (2–8°C) in the original carton to
protect the product from light.41 However,
bezlotoxumab must be diluted prior to intra-
venous infusion once a fixed dose is selected for
use. The required volume for the calculated dose
should be removed from the single-dose vial and
then transferred into an intravenous bag contain-
ing either 0.9% sodium chloride injection USP
or 5% dextrose injection USP to prepare a
diluted solution with a final concentration
between 1 and 10 mg/ml.41 The diluted product
can either be stored at room temperature for up
to 16 hours or under refrigeration (2–8°C) for
up to 36 hours, but it should not be frozen.41 If
refrigerated, the intravenous bag needs to reach
room temperature prior to administration.
Central venous access is not required for
bezlotoxumab administration. It should be
administered over 60 minutes using a sterile,
nonpyrogenic, low-protein binding 0.2–5-lm in-
line or add-on filter.41 Bezlotoxumab should not
be administered as an intravenous push or
bolus, and other drugs should not be coadminis-
tered simultaneously through the same infusion
line.41
Warnings, Precautions, and Adverse Reactions
Based on bezlotoxumab clinical trials, no con-
traindications currently exist.41 However, there is
a precaution for bezlotoxumab use in patients
with a history of congestive heart failure (CHF),
and its use should be reserved for cases where
the benefits outweigh the risks in this patient
population.41 In patients with a history of CHF
in phase 3 clinical trials, 12.7% (15/118 patients)
of the bezlotoxumab-treated group and 4.8% (5/
104 patients) of the placebo-treated group devel-
oped serious adverse reactions of CHF during the
12-week study period.57 These adverse reactions
were more common in patients with a previous,
underlying diagnosis of CHF. During the 12-week
follow-up period, 29% of the bezlotoxumab recip-
ients and 33% of the placebo recipients experi-
enced serious adverse reactions including CHF,
which was reported in 2.3% of bezlotoxumab-
treated patients versus 1% of placebo-treated
patients. Furthermore, there were more deaths in
the bezlotoxumab group (23/118 patients
[19.5%]) compared to the placebo group (13/104
patients [12.5%]) in patients with a history of
CHF during the 12-week study period.55 Causes
of death were various and included cardiac fail-
ure, respiratory failure, and infection. In these
clinical studies, it is unclear whether the
preexisting CHF was well controlled in these
patients and whether these patients had reduced
or preserved ejection fraction.
The safety of bezlotoxumab was evaluated in
the MODIFY I and MODIFY II trials.55 Adverse
reactions were reported within the first 4 weeks
for patients who received bezlotoxumab 10 mg/
kg as a single dose while on standard-of-care
antibiotics for treatment of CDI. In the pooled
phase 3 analysis, there were a total of 786 patients
who received bezlotoxumab and 781 who
received placebo. Common adverse effects were
defined as occurring more frequently than pla-
cebo and reported in at least 4% of patients within
the first 4 weeks of infusion. The most common
adverse effects in the bezlotoxumab-treated group
compared to the placebo-treated group were nau-
sea (7% vs 5%), vomiting (3.9% vs 2.7%), fatigue
(2.3% vs 1.5%), pyrexia (5% vs 3%), headache
(4% vs 3%), and diarrhea (6.0% vs 5.8%).
With regard to infusion-related reactions, 10%
and 8% of bezlotoxumab-treated patients
and placebo-treated patients, respectively, experi-
enced at least one infusion-specific adverse
reaction on the day of or the day after administra-
tion.55 Infusion-specific adverse reactions reported
in at least 0.5% of bezlotoxumab recipients and at
a frequency greater than that in placebo recipients
included nausea (3%), fatigue (1%), pyrexia (1%),
dizziness (1%), headache (2%), dyspnea (1%),
and hypertension (1%). None of the evaluable
patients in the MODIFY I and MODIFY II trials
treated with bezlotoxumab tested positive for
treatment-emergent anti-bezlotoxumab antibodies.
During the 12-week follow-up period, overall
mortality rates during this time period were 7.1%
and 7.6% in the bezlotoxumab-treated patients
and placebo-treated patients, respectively.55
No studies were performed to test the potential
of carcinogenicity or impairment of fertility with
bezlotoxumab administration in animals.41 In
addition, no information exists regarding the
administration of bezlotoxumab during pregnancy
or lactation.41 Because the MODIFY I and MOD-
IFY II trials only included patients aged 18 years
or older, the safety and efficacy of bezlotoxumab in
the pediatric population are unknown.41
Clinical Trial Experience
Phase 2 Clinical Trials
A phase 2, multicenter, randomized, double-
blind, placebo-controlled trial evaluated the effi-
cacy of bezlotoxumab with actoxumab (single
10-mg/kg intravenous dose of each agent) added
to standard-of-care antibiotics (metronidazole or
vancomycin [fidaxomicin was not FDA approved
during this study period]) for the preven-
tion of CDI recurrence.53 The primary endpoint
was the recurrence of CDI during a 12-week fol-
low-up period, which was defined as a new epi-
sode of diarrhea associated with a new positive
stool toxin test after the resolution of the initial
CDI diarrheal episode and after discontinuation
of metronidazole or vancomycin. Enrolled
patients included those with their first episode
of CDI as well as those with recurrent CDI to
assess the preventive effects of these agents. Sec-
ondary outcomes measured included the severity
of the initial episode, number of days to resolu-
tion of the initial episode, and antibiotic treat-
ment failure. Diarrhea was defined as three or
more unformed stools per day for at least two
consecutive dates or more than six unformed
stools in 1 day. The enzyme immunoassay (EIA)
diagnostic testing method was used for TcdA
and TcdB detection at each study site.
A total of 200 patients (≥ 18 yrs of age) with
diarrhea and a positive stool test for C. difficile
toxin in the 14-day period prior to enrollment
were included in the study (101 patients in the
bezlotoxumab-actoxumab group and 99 patients
in the placebo group). The mean age of
patients was 64 years (range 20–101 yrs), and
the two groups were well matched in their
baseline characteristics. The rate of CDI recur-
rence was lower in the bezlotoxumab-actoxu-
mab group compared to placebo (7% vs 25%,
95% confidence interval [CI] 7–29%, p<0.001).
Furthermore, the relative risk (RR) of recur-
rence was significantly lower (RR 0.23, 95% CI
0.08–0.54, p=0.01) and the time to CDI recur-
rence was significantly longer (p<0.001) in the
monoclonal antibody arm compared with the
placebo arm.
The time to diarrhea resolution, number of
days hospitalized for the initial episode, and
diarrhea severity were similar between the two
groups. Eighteen patients in the bezlotoxumab-
actoxumab group and 28 patients in the placebo
group reported at least one serious adverse
effect, but this difference was not found to be
statistically significant (p=0.09). The most com-
monly reported adverse effect was headache in
both groups. Treatment with bezlotoxumab-
actoxumab was effective with either concurrent
metronidazole or vancomycin treatment in
patients with hypervirulent strain BI/NAP1/027
or nonepidemic strains of C. difficile, and in
patients with their first episode of CDI or those
with multiple CDI recurrences.
Data from the placebo group (n=99) were
analyzed to identify risk factors associated with
recurrent CDI.58 Of the 99 patients in the pla-
cebo group, 25 patients (25.3%) had recurrent
CDI within the 12-week follow-up period. The
presence of serum anti-toxin B antibodies was
found to be protective against CDI recurrence,
but no correlation was found between serum
anti–toxin A antibodies and CDI recurrence.
Phase III Clinical Trials
The safety and efficacy of bezlotoxumab in
patients receiving standard-of-care antibiotics
for primary or recurrent CDI were evaluated in
two 12-week, phase 3, double-blind, placebo-
controlled studies, MODIFY I and MODIFY II.55
These studies included 2655 patients at 322 sites
in 30 countries from November 1, 2011, through
May 15, 2015, who were 18 years of age or
older with a confirmed diagnosis of CDI. Effi-
cacy was assessed in a modified intention-to-
treat (mITT) group, which included all patients
who received the study infusion, had a positive
baseline stool test for toxigenic C. difficile, and
began receiving standard-of-care antibiotics
before or within 1 day after receiving the study
infusion. Patients were included in the mITT
population regardless if initial clinical cure was
achieved or not after receiving standard-of-care
antibiotics for CDI. Patients were excluded from
these studies if surgery was required or if they
had a prior diagnosis of chronic, uncontrolled
diarrhea. Safety was evaluated in an as-treated
population, which included all patients who
received the study infusion. CDI recurrence was
defined as the development of a new episode of
diarrhea associated with a positive stool test for
toxigenic C. difficile after initial clinical cure of
the baseline CDI within a 12-week follow-up
period.
The primary endpoint was the proportion of
patients with recurrent CDI during the 12 weeks
of follow-up in the mITT population following
administration of bezlotoxumab alone, actox-
umab alone (MODIFY I only), bezlotoxumab-
actoxumab, or placebo. Initial clinical cure was
defined as the absence of diarrhea for two con-
secutive days after the completion of standard-
of-care antibiotics for ≤ 16 days. Secondary
endpoints included the rate of recurrent CDI in
the subgroup of patients who had initial clinical
cure in the mITT population and the rate of
sustained or global cure in the mITT population,
which included patients with initial clinical cure
and no recurrent CDI through the 12-week fol-
low-up period. Permitted stool testing methods
for diagnosis of baseline CDI included cell cyto-
toxicity assays, culture with toxin detection or
strain typing, toxin EIA tests, or polymerase
chain reaction (PCR) assays.
Patients received a single infusion of the study
drug at some time point during the 10–14-day
course of standard-of-care antibiotics (metron-
idazole, vancomycin, or fidaxomicin). Patients
who received vancomycin or fidaxomicin were
also eligible to receive intravenous metronida-
zole as combination therapy. The administration
day for the study infusion as well as the choice
of antibiotic therapy was at the discretion of the
health care provider. The baseline characteristics
were well matched across all treatment arms in
both the MODIFY I and MODIFY II trials, with
a median age of 65 years, 57% female, 85%
white, and 68% hospitalized.
The MODIFY I trial involved 158 investigator
sites in 19 countries and was funded by Merck
& Co., Inc. In this study, 1396 patients were
included in the mITT population: bezlotox-
umab-actoxumab (383 patients); actoxumab
alone (232 patients); bezlotoxumab alone (386
patients); or placebo (395 patients).55 A total of
1224 patients completed the 12-week follow-up
period. The actoxumab treatment arm was
stopped early after an interim analysis demon-
strated that actoxumab alone was associated
with significantly higher rates of recurrent infec-
tion compared to the actoxumab-bezlotoxumab
group (p=0.02). More deaths and serious
adverse effects were also observed in the actox-
umab group compared to the placebo group.
For the primary endpoint, the rate of recur-
rent CDI at week 12 was significantly lower in
patients treated with bezlotoxumab alone com-
pared with those treated with placebo, as
depicted in Table 1. Initial clinical cure was
achieved in 77.5% (299/386) of patients in the
bezlotoxumab group compared to 82.8% (327/
395) in the placebo group (adjusted difference
5.3 percentage points, 95% CI 10.9 to 0.3,
p=0.0643). In patients with initial clinical cure,
the differences in the rate of recurrent CDI for
the bezlotoxumab group (67/299 [22.4%]) com-
pared with the placebo group (109/327 [33.3%])
(adjusted difference 10.8 percentage points;
95% CI 17.7 to 3.8; p=0.0026) were similar
to those found in the mITT population
(Table 1). In addition, the proportion of patients
with sustained cure did not differ significantly
between the bezlotoxumab group (232/386
[60.1%]) or the placebo group (218/395
[55.2%]) (adjusted difference 4.8 percentage
points, 95% CI 2.1 to 11.7, p=0.1722).
The MODIFY II trial involved 171 investigator
sites in 17 countries and was funded by Merck
& Co., Inc. In this study, 1163 patients were
included in the mITT population: bezlotox-
umab-actoxumab (390 patients); bezlotoxumab
(395 patients); or placebo (378 patients).55 No
patients received actoxumab alone due to the
interim analysis performed in the MODIFY I
trial. A total of 966 patients completed the
12-week follow-up period.
For the primary endpoint, the rate of recur-
rent CDI at week 12 was significantly lower in
patients treated with bezlotoxumab alone com-
pared to placebo, as represented in Table 1. Ini-
tial clinical cure was achieved in 82.5% (326/
395) of patients in the bezlotoxumab group
compared to 77.8% (294/378) of patients in the
placebo group (adjusted difference 4.8 percent-
age points, 95% CI 0.9 to 10.4, p=0.0962). In
patients with initial clinical cure, the differences
in the rate of recurrent CDI for the bezlotox-
umab group (62/326 [19.0%]) compared to the
placebo group (97/294 [33.0%]) (adjusted differ-
ence 13.7 percentage points, 95% CI 20.4 to
6.9, p<0.001) were similar to those found in
the mITT population (Table 1). Unlike the
MODIFY I trial, the proportion of patients with
sustained cure was significantly higher for the
bezlotoxumab group (264/395 [66.8%]) com-
pared to the placebo group (197/378 [52.1%])
(adjusted difference between bezlotoxumab and
placebo 14.6 percentage points; 95% CI, 7.7 to
21.4; p<0.0001).
In an analysis of pooled data from the MOD-
IFY I and MODIFY II trials, the rate of recurrent
CDI at week 12 was significantly lower in
patients treated with bezlotoxumab alone com-
pared to placebo (Table 1).55 Initial clinical cure
was achieved in 80.0% (625/781) of patients in
the bezlotoxumab group and 80.3% (621/773) of
patients in the placebo group (adjusted differ-
ence 0.3 percentage points, 95% CI 4.3 to
3.7, p=0.8832). In patients with initial clinical
cure, the differences in the rate of recurrent CDI
for the bezlotoxumab group (129/625 [20.6%])
compared to placebo (206/621 [33.2%]) (ad-
justed difference 12.2 percentage points, 95%
CI 17.1 to 7.4, p<0.0001) were similar to
those found in the mITT population (Table 1).
Overall, the proportion of patients with sus-
tained cure was significantly higher for patients
who received bezlotoxumab alone (496/781
[63.5%]) compared with those who received pla-
cebo (415/773 [53.7%]) (adjusted difference
between bezlotoxumab and placebo, 9.7 percent-
age points, 95% CI 4.8–14.5, p<0.0001). In the
MODIFY I trial, treatment with the combination
of bezlotoxumab-actoxumab did not provide
added efficacy over bezlotoxumab alone.55
This suggests the neutralization of TcdB alone to
be sufficient to reduce the risk of CDI recur-
rence in humans. As such, the addition of actox-
umab to bezlotoxumab for prevention of CDI
recurrence would increase the cost of therapy
and may pose additional risks.
It is important to recognize that the pooled
analysis of sustained cure in the Phase III MOD-
IFY trials does not represent a more extensive
and individual analysis. In a subgroup analysis
of the pooled MODIFY data, CDI recurrence
rates were lower for bezlotoxumab alone com-
pared to placebo for all subgroups evaluated.55
Statistically significant decreases in recurrence
rates were seen in patients ≥ 65 years of age,
patients experiencing recurrent episodes of CDI,
immunocompromised patients (based on medi-
cal history or use of immunosuppressive ther-
apy), and patients with severe CDI. Notably,
rates of recurrence in patients with the hypervir-
ulent strain, BI/NAP1/027, were numerically, but
not statistically significantly, lower in the
Table 1. Rates of Clostridium difficile Infection Recurrences in the Modified Intention-to-Treat Analysis of Phase III
Clinical Trials of Bezlotoxumab
Trial
Clostridium difficile Infection Recurrence Rate at Week 12
No. (%) of Patients
Receiving Bezlotoxumab
No. (%) of Patients
Receiving Placebo
Absolute Difference in Clostridium
difficile Infection Recurrence Rate
(Bezlotoxumab – Placebo)
MODIFY I (phase 3)55 67/386 (17.4) 109/395 (27.6) 10.1% (95% CI 15.9 to 4.3), p=0.0003
MODIFY II (phase 3)55 62/395 (15.7) 97/378 (25.7) 9.9% (95% CI 15.5 to 4.3), p=0.0003
MODIFY I and MODIFY
II pooled data55
129/781 (16.5) 206/773 (26.6) 10.0% (95% CI 14.0 to 6.0), p<0.0001
CI = confidence interval.
bezlotoxumab group (21/89 [23.6%]) compared
to the placebo group (34/100 [34.0%]).55 How-
ever, a statistically significant decrease in recur-
rence was seen for patients with the BI/NAP1/
027 strain who received the combination of
bezlotoxumab plus actoxumab (9/76 [11.8%])
compared to placebo (34/100 [34%]). This find-
ing suggests that the addition of actoxumab to
bezlotoxumab may provide a greater benefit for
patients with the BI/NAP1/027 strain compared
to bezlotoxumab alone.
Based on the pooled data analysis and abso-
lute risk reduction (ARR) data presented in
Table 1, the number needed to treat (NNT) to
prevent one CDI recurrence episode was 10.55
However, the NNT was six among patients with
the identified risk factors of age ≥ 65 years
(15.4% had CDI recurrence with bezlotoxumab
compared to 31.4% with placebo) and those
with at least one previous CDI in the past
6 months (25.0% had CDI recurrence with
bezlotoxumab compared to 41.1% with pla-
cebo).55 At 6-, 9-, and 12-month follow-up peri-
ods, C. difficile colonization was similar in all
study groups, ranging from 16.3% to 32.8%.59
This suggests that the efficacy of bezlotoxumab
observed during the 12-week follow-up period
was attributable to sustained protection from
CDI recurrence rather than a delay in the onset
of a recurrent CDI.59 In addition, most CDI
recurrences (71%) occurred within 4 weeks after
study infusion.55
Several different testing methods for diagnosis
of CDI were used in the MODIFY trials. A post
hoc pooled analysis was performed to examine
the potential impact of EIA versus PCR diagnos-
tic testing on study outcomes since each method
varies in its predictive value for true positive
CDI.60 Stool testing methods for diagnosis of
baseline CDI included cell cytotoxicity assays,
culture with toxin detection or strain typing,
toxin EIA, or PCR. All permitted commercial
testing methods had the capacity to detect the
presence of TcdB (EIA method) or the TcdB
gene (PCR method) and had a labeled specificity
of ≥ 94%. The EIA testing method was the most
commonly used diagnostic test at baseline, fol-
lowed by PCR, culture with toxin detection or
strain typing, and cell cytotoxicity assay. CDI
recurrence rates were higher when diagnosis was
made by PCR compared with toxin EIA for
bezlotoxumab-treated patients. In contrast, CDI
recurrence rates were similar for diagnoses using
PCR or EIA for placebo-treated patients. The
reduction of CDI recurrence associated with
bezlotoxumab was larger if EIA rather than PCR
was used to diagnose CDI. CDI recurrence rates
among patients diagnosed with EIA were 27.3%
(105/385 patients) in the placebo group versus
14.5% (54/372 patients) in the bezlotoxumab
group. For patients diagnosed with PCR, the
recurrence rates were 26.1% (88/337 patients) in
the placebo group versus 19.6 (70/357 patients)
in the bezlotoxumab group.60
Practical Considerations and Future Directions
Although the MODIFY I and MODIFY II clini-
cal trials provided important evidence to support
the role of bezlotoxumab in the prevention of
CDI recurrence and led to FDA approval for this
agent, several important questions remain. The
duration of benefit after administration of bezlo-
toxumab beyond the 12-week follow-up period
in these trials is unknown. Furthermore, it is
unknown which patient populations are likely to
derive the greatest benefit from bezlotoxumab
administration. Bezlotoxumab is indicated for
patients who are considered high risk for CDI
recurrence, yet these patient populations are not
well defined within the product labeling.
Patients at high risk for recurrence may include
older adults, immunosuppressed hosts, patients
with a history of CDI recurrence, and those
receiving antibiotic therapy.17 The role of bezlo-
toxumab in primary CDI prevention for high-
risk patient groups is another interesting area to
consider for future research in order to deter-
mine if this is both clinically and economically
justifiable.
It is also unclear how CDI recurrence rates
compare between patients who receive bezlotox-
umab and those who receive alternative preven-
tative therapies such as FMT or other novel
approaches in the pipeline for prevention of
CDI. FMT has been demonstrated to be highly
effective in treating CDI as well as reducing CDI
recurrence.38 Although head-to-head trials com-
paring clinical efficacy and safety of FMT to
bezlotoxumab for prevention of CDI recurrence
could be useful, it is important to highlight that
FMT is a treatment modality whereas bezlotox-
umab is only a preventive agent that must be
used in conjunction with CDI treatment agents.
A total of 26 patients (22 in the placebo group,
4 in the bezlotoxumab group) received FMT in
the MODIFY I and II trials, but their outcomes
are not available. Bezlotoxumab may offer an
advantage over FMT in individualized patient-
specific situations, particularly in patients who
do not respond to FMT or those who are unable
to stop antibiotic therapy for other concurrent
infectious diseases indications.
The degree of benefit observed for each speci-
fic standard-of-care antibiotic (metronidazole,
vancomycin, or fidaxomicin) in combination
with bezlotoxumab remains unclear as well since
the MODIFY trials did not provide relative risk
stratification for different antibiotics used with
bezlotoxumab.38, 55 In the pooled analysis of the
MODIFY I and MODIFY II trials, only 4% of
patients received fidaxomicin.55 Fidaxomicin
alone has been associated with a reduction in
CDI recurrence rates among patients treated for
their first CDI episode for the nonvirulent, non-
NAP1/BI/027 strains.7 The additional benefit of
bezlotoxumab in patients treated with fidax-
omicin remains unknown.7, 38 It is also impor-
tant to highlight that the follow-up period to
assess for CDI recurrence was much shorter in
phase 3 clinical trials for fidaxomicin compared
to bezlotoxumab (28 days for fidaxomicin versus
84 days for bezlotoxumab).7, 55 The phase 3
clinical trials that led to the FDA approval of
fidaxomicin excluded patients with more than
one episode of CDI in the previous 3 months,
which may also influence CDI recurrence rates
for patients with multiple CDI recurrences, as
these patients have exposure to multiple antibi-
otic courses for CDI treatment and an altered
gut microbiota.7
In the pooled data analysis of the MODIFY I
and MODIFY II trials, the NNT to prevent
one episode of CDI recurrence was 10.55 In clin-
ical practice, the actual NNT may differ from
this, as the approach to bezlotoxumab use
remains to be determined. In the MODIFY trials,
bezlotoxumab was given to patients being trea-
ted for CDI regardless of risk factors and regard-
less of whether it was a first or recurrent
episode. It is also important to note that there
was a difference in the CDI recurrence rates for
different diagnostic testing methods, with higher
rates of CDI recurrence observed when PCR was
used for diagnosis compared to EIA testing.
Thus, the NNT to prevent recurrence will be
higher than that seen in the clinical trials for
populations in which PCR is the primary diag-
nostic test used. This is an important aspect to
consider when making formulary decisions, par-
ticularly for institutions that solely use PCR
diagnostic testing.
Prior to the widespread adoption of bezlotox-
umab in health care settings, a cost-benefit anal-
ysis needs to be performed to best determine its
role in therapy and to determine whether this
intervention is economically beneficial for health
care institutions and specific health care settings.
With an approximate 10% ARR presented in
phase 3 clinical trials, it will be critical for insti-
tutions to determine whether bezlotoxumab is
economically viable and clinically justifiable
based on their specific institution, patient popu-
lations, and health care–related costs regarding
CDI recurrence. Careful patient selection and
risk stratification may translate into a more cost-
effective approach to decrease CDI recurrence
rates. Optimal timing of administration will also
need to be determined for various patient popu-
lations at high risk for relapse. Third party reim-
bursement, patient location, and urgency of
administration will likely play a role in whether
bezlotoxumab is administered in an outpatient
clinic setting versus an inpatient setting. Bezlo-
toxumab was administered at various time
points during standard-of-care antibiotics for
CDI treatment. Thus, bezlotoxumab administra-
tion potentially could be deferred to the outpa-
tient setting once patients improve clinically to
minimize inpatient-related costs. Based on these
considerations, there are potential concerns and
unresolved issues that should be addressed in
future studies to better characterize the role of
bezlotoxumab in the clinical setting.
Conclusion
Bezlotoxumab, a fully humanized monoclonal
antibody that binds to and neutralizes C. difficile
toxin B, is the first-in-class, FDA-approved agent
to provide passive immunity for the prevention
of CDI recurrence. In clinical studies, bezlotox-
umab was well tolerated and effective for the
reduction of CDI recurrence compared to pla-
cebo. Pharmacoeconomic analyses are needed to
guide cost-effective use. Although much of the
role of bezlotoxumab remains to be revealed by
phase 4 clinical experience, this agent is a wel-
comed addition to the CDI management arma-
mentarium, where limited therapeutic options
exist.
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